Victoria Socha

DocwireNews

Kidney transplant recipients with delayed graft function face worse short- and long-term outcomes than those without delayed graft function. According to A. Perez-Gutierrez and colleagues at the University of Chicago, Chicago, Illinois, there are no biomarkers to predict outcomes in patients with delayed graft function.Serum &szlig;2 microglobulin is a low-molecular-weight protein that strongly correlates with serum cystatin C and creatinine and is a predictor of cardiovascular events, overall mortality, and graft failure in <a href="https://www.docwirenews.com/latest-nephrology-news/outcomes-among-kidney-transplant-recipients-with-covid-19-2/">kidney transplant</a> recipients. There are few data on the role of the &szlig;2 microglobulin trend in patients with delayed graft function.During a virtual session at the 2021 American Transplant Congress, the researchers reported results of a retrospective study examining the role of the &szlig;2 microglobulin trend in kidney transplant recipients. The presentation was titled The Role of the &szlig;2 Microglobulin Trend in Patients with Delayed Graft Function after Kidney Transplant.The study population included all kidney transplants from deceased donors performed at the center from 2014 to 2017. Exclusions were pediatric and multiple organ transplants. Inclusion criteria were measurements of serum levels of &szlig;2 microglobulin from postoperative day 1 to day 5; &szlig;2 microglobulin trend was defined as the difference between &szlig;2 on postoperative day 4 and &szlig;2 on postoperative day 1. The researchers used univariate and multivariate logistic regression.The analysis included 150 kidney transplant recipients. Of those, 45% (n=68) had delayed graft function (median 7.5 days, range 1-51 days). Fifty percent of the patients with delayed graft function received dialysis for 1 week only. Three patients had primary nonfunction.With the exception of the cause of kidney failure, baseline characteristics of the two groups (with and without delayed graft function) were similar. There was a strong correlation between &szlig;2 microglobulin and delayed graft function (P&lt;.001), and there was a significant correlation between &szlig;2 microglobulin and estimated glomerular filtration rate at 1, 6, and 12 months in all patients (P&lt;.05).In the delayed graft function group, there was correlation between &szlig;2 microglobulin trend and the duration of delayed graft function (P=.05). The correlation was independent of donors after circulatory death and type of kidney storage. There was no association between &szlig;2 microglobulin and mortality or rejection.In conclusion, the researchers said, &ldquo;The &szlig;2 microglobulin trend is a marker of kidney function useful particularly in patients with delayed graft function, because it measures the residual kidney function in the setting of dialysis. Following the trend of &szlig;2 microglobulin in patients with delayed graft function is informative about the duration of the delayed graft function and may help make clinical decisions. Validation of this marker in a larger population of patients with delayed graft function is needed.&rdquo;Source: Perez-Gutierrez A, Bachul P.J., Juengel B, et al. The role of the &nbsp;&szlig;2 microglobulin trend in patients with delayed graft function after kidney transplant. Abstract of a presentation at the virtual American Transplant Congress 2021 (abstract #664), June 6, 2021.

Eva Blondeaux, MD

Risk-Reducing Surgery Linked to Survival in Young BRCA Carriers

Genetics & Breast Cancer

Jordana Jampel

Successful HIV Viral Suppression With At-Home Administration

Modernization and the Rising Burden of IBD: New Insights From a Global Study

Gastroenterology

Latest News

ß2 as Marker of Kidney Function in Patients with Delayed Graft Function

American Transplant Congress 2021

Kidney transplant recipients with delayed graft function face worse short- and long-term outcomes than those without delayed graft function. According to A. Perez-Gutierrez ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe